A medicoeconomic review of early intervention with biologic agents in the treatment of inflammatory bowel diseases

References

• SilverbergMSSatsangiJAhmadTToward an integrated clinical, molecular and serological classification of inflammatory bowel disease: report of a working party of the 2005 Montreal World Congress of GastroenterologyCan J Gastroenterol200519Suppl A536
   PubMed Web of Science ®Google Scholar
• BurischJPedersenNČuković-ČavkaSEast-West gradient in the incidence of inflammatory bowel disease in Europe: the ECCO-EpiCom inception cohortGut201463458859723604131
   PubMed Web of Science ®Google Scholar
• BorgSPerssonUJessTA maximum likelihood estimator of a Markov model for disease activity in Crohn’s disease and ulcerative colitis for annually aggregated partial observationsMed Decis Making201030113214219605883
   PubMed Web of Science ®Google Scholar
• MunkholmPLangholzEDavidsenMBinderVDisease activity courses in a regional cohort of Crohn’s disease patientsScand J Gastroenterol19953076997067481535
   PubMed Web of Science ®Google Scholar
• BlomqvistPEkbomAInflammatory bowel diseases: health care and costs in Sweden in 1994Scand J Gastroenterol19973211113411399399395
   PubMed Web of Science ®Google Scholar
• MowatCColeAWindsorAGuidelines for the management of inflammatory bowel disease in adultsGut201160557160721464096
   PubMed Web of Science ®Google Scholar
• BlonskiWBuchnerAMLichtensteinGRInflammatory bowel disease therapy: current state-of-the-artCurr Opin Gastroenterol201127434635721654383
   PubMed Web of Science ®Google Scholar
• ChevauxJ-BVavrickaSRRoglerGLakatosPLSchoepferAPeyrin-BirouletLMucosal healing with anti-TNF antibodiesDigestion201286Suppl 1162223051722
   PubMed Web of Science ®Google Scholar
• OdesSHow expensive is inflammatory bowel disease? A critical analysisWorld J Gastroenterol200514436641664719034966
   PubMed Web of Science ®Google Scholar
• BosaniAArdizonneSPorroGBBiologic targeting in the treatment of inflammatory bowel diseasesBiologics20093779719707398
   PubMedGoogle Scholar
• FordACSandbornWJKhanKJEfficacy of biological therapies in inflammatory bowel disease: systematic review and meta-analysisAm J Gastroenterol2011106464465921407183
   PubMed Web of Science ®Google Scholar
• KawalecPMikrutAWiśniewskaNPilcATumor necrosis factor-α antibodies (infliximab, adalimumab and certolizumab) in Crohn’s disease: systematic review and meta-analysisArch Med Sci2013976577924273556
   PubMed Web of Science ®Google Scholar
• HanauerSBSandbornWJRutgeertsPHuman anti-tumor necrosis monoclonal antibody (adalimumab) in Crohn’s disease: the CLASSIC-1 trialGastroenterology2006130232333316472588
   PubMed Web of Science ®Google Scholar
• SandbornWJRutgeertsPEnnsRAdalumumab induction therapy for Crohn’s disease previously treated with infliximab: a randomized trialAnn Intern Med20071461282983817470824
   PubMed Web of Science ®Google Scholar
• SandbornWJSchreiberSFeaganBGCertolizumab pegol for active Crohn’s disease: a placebo-controlled, randomized trialClin Gastroenterol Hepatol20119867067821642014
   PubMed Web of Science ®Google Scholar
• WinterTAWrightJGhoshSIntravenous CDP870, a PEGylated Fab’ fragment of a humanized antitumour necrosis factor antibody, in patients with moderate-to-severe Crohn’s disease; an exploratory studyAliment Pharmacol Ther20042011–121337134615606396
   PubMed Web of Science ®Google Scholar
• SchreiberSLawranceICThomsonORandomized clinical trial: certolimumab pegol for fistulas in Crohn’s disease: sub-group results from a placebo-controlled studyAliment Pharmacol Ther201133218519321083671
   PubMed Web of Science ®Google Scholar
• ColombelJFSandbornWJReinischWInfliximab, azathioprine, or combination therapy for Crohn’s diseaseN Engl J Med2010362151383139520393175
   PubMed Web of Science ®Google Scholar
• TarganSRHanauerSBvan DeventerSJA short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn’s disease. Crohn’s disease cA2 Study GroupN Engl J Med199733715102910359321530
   PubMed Web of Science ®Google Scholar
• D’HaensGBaertFvan AsscheGEarly combined immunosuppression or conventional management in patients with new diagnosed Crohn’s disease: an open randomized trialLancet2008371961366066718295023
   PubMed Web of Science ®Google Scholar
• TarganSRFeaganBGFedorakRNNatalizumab for the treatment of active Crohn’s disease: results of the ENCORE trialGastroenterology200713651672168317484865
   PubMed Web of Science ®Google Scholar
• SandbornWJColombelJFEnnsRNatalizumab induction and maintemence therapy for Crohn’s diseaseN Engl J Med2005353181912192516267322
   PubMed Web of Science ®Google Scholar
• RutgeertsPSandbornWJFeaganBGInfliximab for induction and maintenance therapy for ulcerative colitisN Engl J Med2005353232462247616339095
   PubMed Web of Science ®Google Scholar
• ReinischWSandbornWJHommesDWAdalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomised controlled trialGut201160678078721209123
   PubMed Web of Science ®Google Scholar
• SandbornWJvan AsscheGReinischWAdalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitisGastroenterology2012142525726522062358
   PubMed Web of Science ®Google Scholar
• SandbornWJFeaganBGMaranoCSubcutaneous golimumab induces clinical response and remission in patients with moderate-to-severe ulcerative colitisGastroenterology20141461859523735746
   PubMed Web of Science ®Google Scholar
• StidhamRWLeeTCHHigginsPDRSystematic review with network meta-analysis: the efficacy of anti-TNF agents for the treatment of Crohn’s diseaseAliment Pharmacol Ther2014391213991362
   Web of Science ®Google Scholar
• RutgeertsPDiamondRHBalaMScheduled maintenance treatment with infliximab is superior to episodic treatment for the healing of mucosal ulceration associated with Crohn’s diseaseGastrointest Endosc200663343344216500392
   PubMed Web of Science ®Google Scholar
• SchnitzlerFFidderHFerranteMMucosal healing predicts long-term outcome of maintenance therapy with infliximab in Crohn’s diseaseInflamm Bowel Dis20091591295130119340881
   PubMed Web of Science ®Google Scholar
• GisbertJPPanesJLoss of response and requirement of infliximab dose intensification in Crohn’s disease: a reviewAm J Gastroenterol2009104376076719174781
   PubMed Web of Science ®Google Scholar
• RicartEOrdasIPanesJAnti-TNF antibody therapy in Crohn’s disease: the risk of a switchGut201261216917022068167
   PubMed Web of Science ®Google Scholar
• AllezMVermeireSMozziconacciNThe efficacy and safety of a third anti-TNF monoclonal antibody in Crohn’s disease after failure of two other anti-TNF antibodiesAliment Pharmacol Ther20103119210119709098
   PubMed Web of Science ®Google Scholar
• PanaccioneRGhoshSMiddletonSCombination therapy with infliximab and azathioprine is superior to monotherapy with either agent in ulcerative colitisGastroenterology2014146239240024512909
   PubMed Web of Science ®Google Scholar
• LvRQiaoWWuZTumor necrosis factor alpha blocking agents as treatment for ulcerative colitis intolerant or refractory to conventional medical therapy: a meta-analysisPLos One201491e8669224475168
   PubMed Web of Science ®Google Scholar
• LaharieDBourreilleABrancheJCiclosporin versus infliximab in patients with severe ulcerative colitis refractory to intravenous steroids: a parallel, open-label randomized controlled trialLancet201238098571909191523063316
   PubMed Web of Science ®Google Scholar
• StidhamRWLeeTCHigginsPDSystematic review with network meta-analysis: the efficacy of anti-tumour necrosis factor-alpha agents for the treatment of ulcerative colitisAliment Pharmacol Ther201439766067124506179
   PubMed Web of Science ®Google Scholar
• SandbornWJGasinkCGaoLLUstekinumab induction and maintenance therapy in refractory Crohn’s diseaseN Engl J Med2012367161519152823075178
   PubMed Web of Science ®Google Scholar
• LobatónTVermeireSVan AsscheGRutgeertsPReview article: anti-adhesion therapies for inflammatory bowel diseaseAliment Pharmacol Ther201439657959424479980
   PubMed Web of Science ®Google Scholar
• SandbornWJFeaganBGRutgeertsPVedolizumab as induction and maintenance therapy for Crohn’s diseaseN Engl J Med2013369871172123964933
   PubMed Web of Science ®Google Scholar
• ParikhALeachTWyantTVedolizumab for the treatment of active ulcerative colitis: a randomized controlled phase 2 dose-ranging studyInflamm Bowel Dis20121881470147922147460
   PubMed Web of Science ®Google Scholar
• VermeireSO’ByrneSKeirMEtrolizumab as induction therapy for ulcerative colitis: a randomized, controlled, phase 2 trialLancet2014384994030931824814090
   PubMed Web of Science ®Google Scholar
• JuilleratPWasanSKFowlerSAEfficacy and safety of natalizumab in Crohn’s disease patients treated at 6 Boston academic hospitalsInflamm Bowel Dis201319112457246323962896
   PubMed Web of Science ®Google Scholar
• SakurabaAKeyashianKCorreiaCNatalizumab in Crohn’s disease: results from a US tertiary inflammatory bowel disease centerInflamm Bowel Dis201319362162623429449
   PubMed Web of Science ®Google Scholar
• SilversteinMDLoftusEVSandbornWJClinical course and costs of care for Crohn’s disease: Markov model analysis of a population-based cohortGastroenterology19991171495710381909
   PubMed Web of Science ®Google Scholar
• HayARHayJWInflammatory bowel disease: medical cost algorithmsJ Clin Gastroenterol19921443183271607608
   PubMed Web of Science ®Google Scholar
• FeaganBGVreelandMGLarsonLRBalaMVAnnual cost of care for Crohn’s disease: a payor perspectiveAm L Gastroenterol200095819551960
   PubMed Web of Science ®Google Scholar
• CohenRDLarsonLRRothJMBeckerRVMummertLLThe cost of hospitalization in Crohn’s diseaseAm J Gastroenterol200095252453010685762
   PubMed Web of Science ®Google Scholar
• BernsteinCNPapineauNZajaczkowskiJRawsthornePOkruskoGBlanchardJFDirect hospital costs for patients with inflammatory bowel disease in a Canadian tertiary care university hospitalAm J Gastroenterol200095367768310710056
   PubMed Web of Science ®Google Scholar
• BassiADoddSWilliamsonPBodgerKCost of illness of inflammatory bowel disease in the UK: a single centre retrospective studyGut200453101471147815361497
   PubMed Web of Science ®Google Scholar
• EbingerMLeidlRThomasSCost of outpatient care in patients with inflammatory bowel disease in a German university hospitalJ Gastroenterol Hepatol200419219219914731130
   PubMed Web of Science ®Google Scholar
• OdesSVardiHFrigerMCost-analysis and cost-determinants in a European inflammatory bowel disease inception cohort with 10 years follow-up evaluationGastroenterology2006131371972816952541
   PubMed Web of Science ®Google Scholar
• BernsteinCNLongobardiTFinlaysonGBlanchardJFDirect medical costs of managing IBD patients: a population-based studyInflamm Bowel Dis20121881498150822109958
   PubMed Web of Science ®Google Scholar
• Van der WalkMEMangenMJLeendersMHealthcare costs of inflammatory bowel disease have shifted from hospitalization and surgery towards anti-TNF therapy: results from the COIN studyGut2014631727923135759
   PubMed Web of Science ®Google Scholar
• BenediniVCaporasoNCorazzaGRBurden of Crohn’s disease: economics and quality of life aspects in ItalyClinicoecon Outcomes Res2012420921822866007
   PubMedGoogle Scholar
• SaroCde la CobaCCasadMAMoralesJMOteroBResource use in patients with Crohn’s disease treated with infliximabAliment Pharmacol Ther200726101313132317850419
   PubMed Web of Science ®Google Scholar
• LoomesDETeshimaCJacobsPFedorakRNHealth care resource use and cost in Crohn’s disease before and after infliximabCan J Gastroenterol201125949750221912761
   PubMed Web of Science ®Google Scholar
• Cost-Effectiveness Analysis Registry [homepage on the Internet] Available from: https://research.tufts-nemc.org/cearBoston, MATufts Medical CenterAccessed August 29, 2014
   Google Scholar
• SaitoSShimizuUNanZEconomic impact of combination therapy with infliximab plus azathioprine for drug-refractory Crohn’s disease: a cost-effectiveness analysisJ Crohn’s Colitis20137216717422626508
   PubMedGoogle Scholar
• MarchettiMLiberatoNLDi SabatinoACorazzaGRCost-effectiveness of top-down versus step-up strategies in patients with newly diagnosed active luminal Crohn’s diseaseEur J Health Econ201314685386122975794
   PubMed Web of Science ®Google Scholar
• TangDHArmstrongEPLeeJKCost-utility analysis of biologic treatments for moderate-to-severe Crohn’s diseasePharmacotherapy201232651552622528603
   PubMed Web of Science ®Google Scholar
• BlackhouseGAssasiNXieFCanadian cost-utility analysis of initiation and maintenance treatment with anti-TNF-α drugs for refractory Crohn’s diseaseJ Crohn’s Colitis201261778522261531
   PubMedGoogle Scholar
• AnanthankrishnanANHurCKorzenikJRCertolizumab pegol compared to natalizumab in patients with moderate to severe Crohn’s disease: results of a decision analysisDig Dis Sci201257247248021909990
   PubMed Web of Science ®Google Scholar
• YuAPJohnsonSWangSTCost utility of adalimumab versus infliximab maintenance therapies in the United States for moderately to severely active Crohn’s diseasePharmacoeconomics200927760962119663531
   PubMed Web of Science ®Google Scholar
• BodgerKKikuchiTHughesDCost-effectiveness of biological therapy for Crohn’s disease: Markov cohort analyses incorporating United Kingdom patient-level cost dataAliment Pharmacol Ther200930326527419438428
   PubMed Web of Science ®Google Scholar
• LoftusEVJrJohnsonSJYuAPWuEQChaoJMulaniPMCost-effectiveness of adalimumab for the maintenance of remission in patients with Crohn’s diseaseEur J Gastroenterol Hepatol200921111302130919465858
   PubMed Web of Science ®Google Scholar
• LindsayJPunekarYMorrisJChung-FayeGHealth-economic analysis: Cost-effectiveness of scheduled maintenance treatment with infliximab for Crohn’s disease – modelling outcomes in active luminal and fistulising disease in adultsAliment Pharmacol Ther2008281768718410558
   PubMed Web of Science ®Google Scholar
• KaplanGGHurCKorzenikJSandsBEInfliximab dose-escalation vs initiation of adalimumab for loss of response in Crohn’s disease: a cost-effectiveness analysisAliment Pharmacol Ther20072611–121509152017931345
   PubMed Web of Science ®Google Scholar
• PunekarYSHawkinsNCost-effectiveness of infliximab for the treatment of acute exacerbations of ulcerative colitisEur J Health Econ2010111677619844750
   PubMed Web of Science ®Google Scholar
• XieFBlackhouseGAssasiNGaebelKRobertsonDGoereeRCost-utility analysis of infliximab and adalimumab for refractory ulcerative colitisCost Eff Resour Alloc20091172020003364
   PubMedGoogle Scholar
• TsaiHHPunekarYSMorrisJFortunPA model of the long-term cost-effectiveness of scheduled maintenance treatment with infliximab for moderate-to-severe ulcerative colitisAliment Pharmacol Ther200828101230123918729845
   PubMed Web of Science ®Google Scholar
• TangDHHarringtonARLeeJKLinMArmstrongEPA systematic review of economic studies on biological agents used to treat Crohn’s diseaseInflamm Bowel Dis201319122673269423792552
   PubMed Web of Science ®Google Scholar
• RoglerGBernsteinCNAjitSRole of biological therapy for inflammatory bowel disease developing countriesGut201261670671221997549
   PubMed Web of Science ®Google Scholar
• SinghJAWellsGAChristensenRAdverse effects of biologics: a network meta-analysis and Cochrane overviewCochrane Database Syst Rev21620112CD00879421328309
   PubMed Web of Science ®Google Scholar
• SinghJAKumarNLoftusEVJrKaneSVNeurological complications in patients with inflammatory bowel disease: increasing relevance in the era of biologicsInflamm Bowel Dis201319486487222552994
   PubMed Web of Science ®Google Scholar
• GhoshSMitchellRImpact of inflammatory bowel disease on quality of life: results of the European Federation of Crohn’s and Ulcerative Colitis Associations (EFCCA) patient surveyJ Crohn’s Colitis20071102021172179
   PubMedGoogle Scholar